AbbVie Inc. Quarterly Deferred Income Tax Expense (Benefit) in USD from Q1 2020 to Q1 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
AbbVie Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2020 to Q1 2024.
- AbbVie Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$389M, a 45.7% decline year-over-year.
- AbbVie Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$2.89B, a 49.6% decline from 2022.
- AbbVie Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$1.93B, a 115% decline from 2021.
- AbbVie Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was -$898M, a 61.4% increase from 2020.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)